Hybrigenics obtains € 1.4 million from OSEO to develop inecalcitol for the treatment of prostate cancer

BIOBASE Releases a New Range of Products for Plant Researchers

Hybrigenics receives authorization to accelerate inecalcitol dose escalation in Phase II trial for hormone-refractory prostate cancer

Hybrigenics and Servier renew research contract for USP validation in oncology